D. E. Shaw & Co., Inc. Atea Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 193,578 shares of AVIR stock, worth $617,513. This represents 0.0% of its overall portfolio holdings.

Number of Shares

193,578

Holding current value

$617,513

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.17 - $4.02 $144,758 - $183,573	45,665 Added 30.87%	193,578 $648,000
Q2 2024 Aug 14, 2024	SELL	$3.31 - $4.04 $198,090 - $241,777	-59,846 Reduced 28.81%	147,913 $489,000
Q1 2024 May 15, 2024	BUY	$3.09 - $4.56 $69,778 - $102,973	22,582 Added 12.19%	207,759 $839,000
Q4 2023 Feb 14, 2024	BUY	$2.8 - $3.35 $322,638 - $386,013	115,228 Added 164.73%	185,177 $564,000
Q3 2023 Nov 14, 2023	SELL	$3.0 - $3.79 $40,419 - $51,062	-13,473 Reduced 16.15%	69,949 $209,000
Q2 2023 Aug 14, 2023	BUY	$3.21 - $5.06 $108,254 - $170,643	33,724 Added 67.86%	83,422 $311,000
Q1 2023 May 15, 2023	BUY	$3.0 - $4.97 $28,428 - $47,095	9,476 Added 23.56%	49,698 $166,000
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.17 $48,132 - $68,271	11,065 Added 37.95%	40,222 $193,000
Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $160,071 - $256,290	29,157 New	29,157 $166,000
Q1 2022 May 16, 2022	SELL	$5.5 - $9.19 $106,722 - $178,322	-19,404 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.67 - $44.59 $148,828 - $865,224	19,404 New	19,404 $173,000
Q2 2021 Aug 16, 2021	SELL	$19.22 - $59.08 $541,754 - $1.67 Million	-28,187 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$41.42 - $88.44 $1.17 Million - $2.49 Million	28,187 New	28,187 $1.74 Million

Others Institutions Holding AVIR

# of Institutions

112

Shares Held

52.4M

Call Options Held

900

Put Options Held

126K

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $266M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account